Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gentibio Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.gentibio.com/
Year Founded: 2020
Status: Private
BioCentury | Oct 1, 2024
Management Tracks
Prothena names Swanson CDO
Plus: Chris Williams at the helm of Culture, GentiBio scoops up former Structure CMO and updates on Burning Rock, National Resilience and Grünenthal
BioCentury | Oct 3, 2023
Management Tracks
Affibody names Peter Zerhouni CFO
Plus: Restructuring at Kezar as CEO, CMO step down, and updates from Atomwise, Aura, Twist, Acelyrin and more
BioCentury | Aug 10, 2022
Deals
BMS brings immunology, cell therapy expertise to GentiBio’s Tregs in IBD pact
Preclinical biotech to identify targets, develop up to three therapies alongside pharma
BioCentury | Jun 3, 2022
Management Tracks
AbbVie’s Severino joins Flagship’s Tessera as CEO
Plus new CFO, CMO at Renibus, and updates from Bayer, Gilead, Shionogi and more
BioCentury | Feb 11, 2022
Management Tracks
Silberstein joins GentiBio as CFO
Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Jan 22, 2022
Data Byte
The largest A rounds of 2021
At least 10 therapeutics companies raised series A rounds of
BioCentury | Nov 29, 2021
Finance
U.S. crossovers help Quell raise $156M as Treg platform heads toward clinic
Series B syndicate for London biotech co-led by slate of U.S. and European investors
BioCentury | Aug 14, 2021
Product Development
Growing list of Treg start-ups — who, what and how much more: Data Byte
With new funding comes more details on company platforms
BioCentury | Aug 12, 2021
Product Development
GentiBio champions build-a-Treg approach with $157M series A
The newco is the latest to indicate Treg manufacturing will be an in-house affair
BioCentury | Aug 5, 2021
Product Development
Sonoma Bio bets on ‘professional’ Tregs and in-house manufacturing with $265M series B
Stealthy Treg company sheds more light on its therapeutic strategy
Items per page:
1 - 10 of 14